TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02056808
Drug: SMT C1100
Normalized name: ZINC OXIDE 2.94 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g / OCTINOXATE 7 g in 100 g TOPICAL CREAM [sMTS Dual HA SUN BLOCK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of safety and pharmacokinetic of different dosages of drug
Study: NCT00240331
Drug: 10mg Rosuvastatin
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00240331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02010099
Drug: PP110 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02127866
Drug: CHF 5259 plus Foster 100/6 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
Study: NCT02127866
Drug: Foster 100/6 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator~Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
Study: NCT06597084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for oral administration, matching the test product. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.
Study: NCT00755976
Drug: sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04583410
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO OF NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day
Study: NCT05896605
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.
Study: NCT04214145
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous infusion of Norepienphrine 20 μg/mL (=NE 4mg \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.03 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.015 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.24 μg/kg/min (=0.8 mL/kg/hr)
Study: NCT00218439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02477215
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
Study: NCT00285857
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin 80 mg/day as 40 mg orally twice daily.~Lovastatin is approved by FDA as a cholesterol-lowering agent.
Study: NCT04052425
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study: NCT03793517
Drug: mBU/CY and ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
Study: NCT03793517
Drug: mBU/CY
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3
Study: NCT03182673
Drug: SHR7390
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg,0.5 mg and 2mg. Multiple tablets of SHR7390 will be administered orally to achieve targeted doses of SHR7390: 0.125 mg-4 mg. Tablets will be administered once daily or for 21 days and discontinued for 7 days with 240 ml water after 2 hours of the meal.
Study: NCT06597825
Drug: root canal irrigation solutions (NaOCl+EDTA, NaOCl+HEDP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After cavity preparation with sterile burs, rubber dam components were applied to the tooth. The root canal filling material was removed via retreatment files. After the working length was determined, in all the groups, the canals were filled with distilled water. S1were taken from the canal after retreatment. Irrigation protocols were applied for 4 groups. S2 were taken from the canal. Intracanal medicament was placed in the root canal, the cavity was securely sealed. After 14 days,the medicament was removed with 10 mL of 17% EDTA and subsequently irrigated with 5 ml of distilled water, S3 was taken by sterile paper points. The final irrigation was performed according to the group to which the tooth belonged, and S4 was collected as before. the root canals were dried with sterile paper points and filled gutta-percha master cones and sealer.
Study: NCT00612963
Drug: Frio Oral Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription Mouth Rinse
Study: NCT03978949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
Study: NCT00505765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo- 3 sprays in each nostril, twice per day
Study: NCT00505765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo- one spray in each nostril, once per day
Study: NCT00683852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
Study: NCT03884829
Drug: CYC140
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYC140 single agent
Study: NCT02427334
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
Study: NCT02427334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: women will receive oral placebo for 14 days starting from the 15th day of menstruation
Study: NCT03520998
Drug: GRF6019
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRF6019 for IV infusion
Study: NCT00416910
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00910650
Drug: non-myeloablative conditioning chemotherapy
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive non-myeloablative conditioning chemotherapy with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days
Study: NCT00423579
Drug: Ezetimibe/Simvastatin 10/20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks
Study: NCT00423579
Drug: simvastatin 40 mg
Normalized name: simvastatin 40 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet containing 40 mg of simvastatin per day for 6 weeks
Study: NCT03530215
Drug: Antineoplastic and Immunomodulating Agents
Normalized name: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
Study: NCT03794310
Drug: NPF-08 （1-day treatment）
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPF-08 will be administered on the day of colonoscopy.
Study: NCT03794310
Drug: NPF-08 （2-day split dose）
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPF-08 will be administered at 2 days divided into the day before and on the day of colonoscopy.
Study: NCT03794310
Drug: Moviprep（1-day treatment）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moviprep will be administered on the day of colonoscopy.
Study: NCT01582932
Drug: Calcipotriene 0.005% Foam
Normalized name: CALCIPOTRIENE 0.005% FOAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
Study: NCT03857854
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo group
Study: NCT01795677
Drug: Ruxolotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor
Study: NCT03697252
Drug: Placebo Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsules
Study: NCT03125395
Drug: LUM/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received LUM/IVA every q12h.
Study: NCT01099722
Drug: Flutiform
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaler 2 puffs bd daily
Study: NCT03159052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, 24 weeks
Study: NCT01099722
Drug: Symbicort Turbohaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs bd daily
Study: NCT02788552
Drug: Thiamine Hydrochloride
Normalized name: Thiamine Hydrochloride
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.
Study: NCT02369874
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT03472339
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group A-Intramuscular diclofenac sodium+oral placebo Group B-Oral diclofenac sodium+ intramuscular placebo
Study: NCT03184688
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided normal saline injection between proximal carpal tunnel and median nerve.
Study: NCT02080715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04109547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets to be taken once-daily for 26 weeks
Study: NCT04218240
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral Placebo
Study: NCT02668510
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injection of normal saline immediately following shockwave therapy
Study: NCT02839096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose placebo that will be used in place of a second dose of ferrous sulfate in the subjects randomized to once daily dosing of ferrous sulfate
Study: NCT01436149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
Study: NCT00573508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Administration
Study: NCT03860870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects ingest placebo tablets
Study: NCT02183948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02079896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00307801
Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill per day taken orally over 7 cycles of 28 pills per cycle
Study: NCT00307801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill per day taken orally over 7 cycles of 28 pills per cycle
Study: NCT03812731
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraoperatively after induction of anaesthesia fentanyl 1-mcg/kg/hour will be administered
Study: NCT02575963
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.
Study: NCT03278275
Drug: One injection of 68Ga-NOTA-AE105
Normalized name: Gel-One Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of 68Ga-NORA-AE105
Study: NCT03094416
Drug: levothyroxine sodium capsule
Normalized name: levothyroxine sodium Oral Capsule
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: after the run-in period, patients will be switched to levothyroxine sodium capsule at the same dose used during run-in
Study: NCT03094416
Drug: Proton pump inhibitor (PPI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: for the whole study duration all subjects will keep taking their proton pump inhibitor medication, as per prescription and as before inclusion
Study: NCT03094416
Drug: Levothyroxine Sodium (LT4) Tablets
Normalized name: Levothyroxine Sodium Tablets
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: during the run-in period, subjects will continue taking their levothyroxine sodium tablet medication as per prescription and as before inclusion
Study: NCT02434640
Drug: BAY1128688
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Single dose and multiple dose for 14 days (postmenopausal women)
Study: NCT02434640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Single dose and multiple dose for 14 days (postmenopausal women)
Study: NCT02434640
Drug: BAY1128688
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: Multiple dose for 28 days (premenopausal women)
Study: NCT01016912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, daily, 48 weeks
Study: NCT00212082
Drug: doxorubicin, docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00284947
Drug: MMF/EC-MPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g MMF or 720mg EC-MPS p.o twice daily
Study: NCT00284947
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids, equivalent to prednisone p.o, ≥ 5mg daily or ≥ 10mg on alternate days
Study: NCT00121251
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04008290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of placebo (0.9% saline solution). The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
Study: NCT04052711
Drug: FMX-101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00648440
Drug: ProAmatine® Tablets 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg, single dose fed
Study: NCT00570986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
Study: NCT00828594
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01263080
Drug: folic acid placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: folic acid placebo 1 tablet QD
Study: NCT01263080
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: folic acid 0.4mg QD
Study: NCT02183662
Drug: Placebo to BI 224436
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04404491
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total.
Study: NCT04404491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo: 200mg,d1,15,29,43,57,I.V
Study: NCT02118467
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
Study: NCT02118467
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
Study: NCT02643212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00432172
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00863278
Drug: Kligman's Trio
Approvals — FDA: no, EMA: no, PMDA: no
Description: The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
Study: NCT03968393
Drug: Non-vitamin K oral anticoagulant (NOAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the intervention arm will be prescribed one of the following NOACs for the duration of follow-up: edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or rivaroxaban 20 mg daily (dose reduction to 15 mg, if applicable). The choice of NOAC will be left up to the participant's prescribing physician.
Study: NCT03815929
Drug: Estradiol 100 Micrograms Patch
Normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard
Study: NCT03815929
Drug: Estradiol Patch
Normalized name: Estradiol Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized
Study: NCT03674411
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg IV over 2 hours
Study: NCT03674411
Drug: Total Body Irradiation (TBI)
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 165 cGy twice daily
Study: NCT00700479
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02431559
Drug: Pegylated Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD was administered as an IV infusion in accordance with local prescribing information.
Study: NCT00305188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00305188
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV administration
Study: NCT02612272
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intra-articular ketorolac
Study: NCT01623570
Drug: Pergoveris: 150IU r-hFSH + 75IU r-hLH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed formulation of two recombinant gonadotropins
Study: NCT01623570
Drug: Menopur: HMG-HP (150 IU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human Menopausal Gonadotropin is an urinary estract from menopausal women containing 150IU of FSH and 150 IU of LH-like activity (HCG)
Study: NCT00434746
Drug: ILV-094
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, ascending doses of 5, 15, 50, 100, 300, and 600 mg IV or SC dose of ILV-094 or placebo
Study: NCT00687193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID, 3 blinded tablets administered BID for 12 weeks
Study: NCT00687193
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg BID, 3 blinded tablets administered BID for 12 weeks
Study: NCT00687193
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg BID, 3 blinded tablets administered BID for 12 weeks
Study: NCT00687193
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg BID, 3 blinded tablets administered BID for 12 weeks
Study: NCT00687193
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg BID, 3 blinded tablets administered BID for 12 weeks
Study: NCT00687193
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg BID, 3 blinded tablets administered BID for 12 weeks
Study: NCT00302731
Drug: Estradiol , estriol , progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00302731
Drug: estradiol, progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00933816
Drug: sorafenib, cisplatin, fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
Study: NCT01692457
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Golimumab will be administered as per the recommended doses. Golimumab 50 mg will be given as a subcutaneous injection once a month, on the same date each month. For rheumatoid arthritis: Golimumab 2 mg/kg will be given as a 30 minute intravenous infusion at Weeks 0 and 4, then every 8 weeks thereafter.
Study: NCT00397501
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2500 mg/day x 2 days; total dose 5000mg Infused over 10mins in 200ml saline beginning immediately after mannitol infusion
Study: NCT03768492
Drug: Caffeine anhydrous 5% added to Lipoderm Cream Base.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine USP Anhydrous 5 gm Ethoxy Digylco Reagent 10 ml Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
Study: NCT04334824
Drug: Angiotensin-converting enzyme (ACE) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to ACE inhibitors will be defined as a prescription for an ACE inhibitor alone or in combination with non-hydrochlorothiazide antihypertensive drugs at cohort entry date.
Study: NCT02986321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo control
Study: NCT01632007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04301271
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks 40 mg Simvastatin add-on